Literature DB >> 15448391

Optimum management of pediatric patients with fever and neutropenia.

Aditya H Gaur1, Patricia M Flynn, Jerry L Shenep.   

Abstract

Fever with neutropenia is a common clinical problem in patients receiving cancer treatment. Prevention and optimum management of infectious complications is critical to the overall success of cancer therapy. This article provides an overview of the current status of this evolving subject. While the basic principles of rapid institution of broad spectrum antibiotics, early intervention with empiric antifungal therapy and continuation of antimicrobials during period of risk are unlikely to change, there is increasing interest in titrating this aggressive approach based on the projected risk of the development of a serious invasive infection. Oral antibiotic therapy and outpatient management are currently being studied in pediatric oncology patients, but even when successful these alternatives to the traditional "in hospital, parenteral antibiotic therapy" approach are unlikely to be applicable in all patient populations and clinical settings. While there is no replacement for clinical acumen and careful monitoring, judicious use of diagnostic resources such as blood cultures and imaging studies is a key component of optimum care. Selection of empiric antibiotics based on ongoing monitoring of antimicrobial susceptibility patterns is emphasized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448391     DOI: 10.1007/bf02730723

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  28 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

Authors:  A S Petrilli; L S Dantas; M C Campos; C Tanaka; V C Ginani; A Seber
Journal:  Med Pediatr Oncol       Date:  2000-02

3.  Oral administration of cefixime to lower risk febrile neutropenic children with cancer.

Authors:  H R Paganini; C M Sarkis; M G De Martino; P A Zubizarreta; L Casimir; C Fernandez; A A Armada; M T Rodriguez-Brieshcke; R Debbag
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

4.  Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.

Authors:  J L Shenep; P M Flynn; D K Baker; S V Hetherington; M M Hudson; W T Hughes; C C Patrick; P K Roberson; J T Sandlund; V M Santana; J W Sixbey; K S Slobod
Journal:  Clin Infect Dis       Date:  2000-12-08       Impact factor: 9.079

5.  Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study.

Authors:  M E Santolaya; M Villarroel; L F Avendaño; J Cofré
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia.

Authors:  R J Klaassen; T R Goodman; B Pham; J J Doyle
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

Authors:  A Cometta; W V Kern; R De Bock; M Paesmans; M Vandenbergh; F Crokaert; D Engelhard; O Marchetti; H Akan; A Skoutelis; V Korten; M Vandercam; H Gaya; A Padmos; J Klastersky; S Zinner; M P Glauser; T Calandra; C Viscoli
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

9.  Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.

Authors:  M Gorschlüter; C Hahn; A Fixson; U Mey; C Ziske; E Molitor; R Horré; T Sauerbruch; G Marklein; I G H Schmidt-Wolf; A Glasmacher
Journal:  Support Care Cancer       Date:  2003-04-11       Impact factor: 3.603

10.  Predicting bacteremia in children with fever and chemotherapy-induced neutropenia.

Authors:  Roland A Ammann; Andreas Hirt; Annette Ridolfi Lüthy; Christoph Aebi
Journal:  Pediatr Infect Dis J       Date:  2004-01       Impact factor: 2.129

View more
  7 in total

1.  Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.

Authors:  Meenakshi Bothra; Rachna Seth; Arti Kapil; S N Dwivedi; Shinjini Bhatnagar; Immaculata Xess
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

Review 2.  Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?

Authors:  Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann
Journal:  GMS Hyg Infect Control       Date:  2016-05-12

3.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

4.  Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey.

Authors:  A Simon; T Lehrnbecher; U Bode; A H Groll; L Tramsen; R Wieland; E Molitor; G Fleischhack; H J Laws
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 5.103

5.  Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Authors:  Arne Simon; Roland A Ammann; Gertrud Wiszniewsky; Udo Bode; Gudrun Fleischhack; Mette M Besuden
Journal:  BMC Infect Dis       Date:  2008-07-29       Impact factor: 3.090

6.  Medical honey for wound care--still the 'latest resort'?

Authors:  Arne Simon; Kirsten Traynor; Kai Santos; Gisela Blaser; Udo Bode; Peter Molan
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-07       Impact factor: 2.629

7.  Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland.

Authors:  Arne Simon; Roland A Ammann; Udo Bode; Gudrun Fleischhack; Hans-Martin Wenchel; Dorothee Schwamborn; Chara Gravou; Paul-Gerhardt Schlegel; Stefan Rutkowski; Claudia Dannenberg; Dieter Körholz; Hans Jürgen Laws; Michael H Kramer
Journal:  BMC Infect Dis       Date:  2008-05-23       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.